A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation

  • J Biol Chem. 2020 Feb 7;295(6):1694-1703. doi: 10.1074/jbc.RA119.011132.
Mélissanne de Wispelaere  1 Margot Carocci  1 Dominique J Burri  1 William J Neidermyer Jr  1 Calla M Olson  2 Imme Roggenbach  1 Yanke Liang  2 Jinhua Wang  2 Sean P J Whelan  1 Nathanael S Gray  2 Priscilla L Yang  3
Affiliations
  • 1. Department of Microbiology and Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02115.
  • 2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215.
  • 3. Department of Microbiology and Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02115. Electronic address: [email protected].
Abstract

Small-molecule inhibitors of translation are critical tools to study the molecular mechanisms of protein synthesis. In this study, we sought to characterize how QL47, a host-targeted, small-molecule Antiviral agent, inhibits steady-state viral protein expression. We demonstrate that this small molecule broadly inhibits both viral and host protein synthesis and targets a translation step specific to eukaryotic cells. We show that QL47 inhibits protein neosynthesis initiated by both canonical cap-driven and noncanonical initiation strategies, most likely by targeting an early step in translation elongation. Our findings thus establish QL47 as a new small-molecule inhibitor that can be utilized to probe the eukaryotic translation machinery and that can be further developed as a new therapeutic agent.

Keywords
anticancer drug; antiviral agent; inhibition mechanism; small molecule; translation.
Products